Clinical Trial Update: Safety and Efficacy of Basiliximab in Calcineurin Inhibitor Intolerant Long-term Kidney Transplant Recipients Treated With Mycophenolic Acid and Steroids [Phase 4]

View source ↗

Summary

Phase 4 study evaluating the safety and efficacy of Basiliximab in long-term kidney transplant recipients intolerant to calcineurin inhibitors who are treated w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplantation

Drugs mentioned

• Simulect (Basiliximab)

Snippet

Sponsor: Novartis | Conditions: Kidney Transplantation, Adverse Effects | Phase 4 | Status: COMPLETED